Ongoing clinical trials of pembrolizumab and nivolumab in cHL
| . | PD-1 inhibitor . | Combination partner . | Clinical setting . | Phase . | No. of patients . | Number . |
|---|---|---|---|---|---|---|
| First-line therapy | Nivolumab | AVD | Advanced stage | 2 | 51 | NCT02181738* |
| Early stage unfavorable | 2 | 110 | NCT03004833* | |||
| High risk or older advanced stage | 1 | 26 | NCT03033914* | |||
| Nivolumab | BV | Ineligible or declined first-line chemotherapy | 2 | 100 | NCT01716806* | |
| Ineligible or declined first-line chemotherapy | 2 | 75 | NCT02758717* | |||
| R/R trials with BV | Pembrolizumab vs BV | R/R | 3 | 300 | NCT02684292* | |
| Nivolumab + BV vs BV alone | R/R | 3 | 340 | NCT03138499* | ||
| Nivolumab | BV | R/R | 2 | 65 | NCT03057795* | |
| R/R | 1/2 | 92 | NCT02572167* | |||
| R/R (young patients age 5-30 y) | 2 | 80 | NCT02927769* | |||
| R/R trials with salvage chemotherapy | Nivolumab | ICE | R/R, before autologous HSCT | 2 | 43 | NCT03016871* |
| Pembrolizumab | 2 | 40 | NCT03077828* | |||
| R/R trials with immunomodulatory agents | Nivolumab | Lenalidomide | R/R | 1/2 | 102 | NCT03015896 |
| Pembrolizumab | R/R | 1/2 | 29 | NCT02875067 | ||
| Nivolumab | Ibrutinib | R/R | 2 | 17 | NCT02940301* | |
| Pembrolizumab | R/R | 1 | 58 | NCT02950220 | ||
| Pembrolizumab | Acalabrutinib | R/R | 2 | 159 | NCT02362035 | |
| R/R trials with combined immune checkpoint agents | Nivolumab | Ipilimumab and/or BV | R/R | 1 | 189 | NCT01896999* |
| Nivolumab | Ipilimumab or lirilumab | R/R | 1 | 375 | NCT01592370 | |
| Nivolumab | BMS-986016 (anti–LAG-3) | R/R | 1/2 | 132 | NCT02061761 | |
| R/R trials in combination with cell-targeted therapies | Pembrolizumab | AFM13 (bispecific anti-CD16/CD30 antibody) | R/R | 1 | 33 | NCT02665650* |
| Nivolumab | EBV-specific T cells | R/R, EBV positive | 1 | 36 | NCT02973113 |
| . | PD-1 inhibitor . | Combination partner . | Clinical setting . | Phase . | No. of patients . | Number . |
|---|---|---|---|---|---|---|
| First-line therapy | Nivolumab | AVD | Advanced stage | 2 | 51 | NCT02181738* |
| Early stage unfavorable | 2 | 110 | NCT03004833* | |||
| High risk or older advanced stage | 1 | 26 | NCT03033914* | |||
| Nivolumab | BV | Ineligible or declined first-line chemotherapy | 2 | 100 | NCT01716806* | |
| Ineligible or declined first-line chemotherapy | 2 | 75 | NCT02758717* | |||
| R/R trials with BV | Pembrolizumab vs BV | R/R | 3 | 300 | NCT02684292* | |
| Nivolumab + BV vs BV alone | R/R | 3 | 340 | NCT03138499* | ||
| Nivolumab | BV | R/R | 2 | 65 | NCT03057795* | |
| R/R | 1/2 | 92 | NCT02572167* | |||
| R/R (young patients age 5-30 y) | 2 | 80 | NCT02927769* | |||
| R/R trials with salvage chemotherapy | Nivolumab | ICE | R/R, before autologous HSCT | 2 | 43 | NCT03016871* |
| Pembrolizumab | 2 | 40 | NCT03077828* | |||
| R/R trials with immunomodulatory agents | Nivolumab | Lenalidomide | R/R | 1/2 | 102 | NCT03015896 |
| Pembrolizumab | R/R | 1/2 | 29 | NCT02875067 | ||
| Nivolumab | Ibrutinib | R/R | 2 | 17 | NCT02940301* | |
| Pembrolizumab | R/R | 1 | 58 | NCT02950220 | ||
| Pembrolizumab | Acalabrutinib | R/R | 2 | 159 | NCT02362035 | |
| R/R trials with combined immune checkpoint agents | Nivolumab | Ipilimumab and/or BV | R/R | 1 | 189 | NCT01896999* |
| Nivolumab | Ipilimumab or lirilumab | R/R | 1 | 375 | NCT01592370 | |
| Nivolumab | BMS-986016 (anti–LAG-3) | R/R | 1/2 | 132 | NCT02061761 | |
| R/R trials in combination with cell-targeted therapies | Pembrolizumab | AFM13 (bispecific anti-CD16/CD30 antibody) | R/R | 1 | 33 | NCT02665650* |
| Nivolumab | EBV-specific T cells | R/R, EBV positive | 1 | 36 | NCT02973113 |
AVD, doxorubicin, vinblastine, and dacarbazine; BV, brentuximab vedotin; HSCT, hematopoietic stem cell transplantation; ICE, ifosfamide, carboplatin, and etoposide.
Trial restricted to patients with cHL. Other trials include other malignancies.